Bringing Precision to CRISPR-Based Genome Editing

Rafi Emmanuel, executive vice president of research and development for Emendo Biotherapeutics, discusses the limits of CRISPR today, the company’s experimental program in severe congenital neutropenia, and how the company is engineering CRISPR to optimize it and make it activity precise.